Sunesis risk/reward attractive at current levels, says Leerink Leerink views the risk/reward for shares of Sunesis as very attractive at current levels and reiterates an Outperform rating on the stock. The firm upped its price target for shares to $14 from $10.
Sunesis downgraded to Hold from Buy at Cantor Cantor Fitzgerald downgraded Sunesis to Hold after removing Qinprezo from its model following the Phase III VALOR trial failure. The firm thinks the stock will be capped to a multiple of cash in the near-term, or roughly $2 per share. Sunesis was also downgraded this morning at Roth Captial.